Ventyx gets $27 million investment from Sanofi

24 September 2024

Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as it announced that French pharma major Sanofi (Euronext: SAN) has agreed to make a $27 million strategic investment in the company]. The closing of the transaction is expected to occur on September 23, 2024.

Expressing welcome for the investment, Ventyx chief executive Raju Mohan said: “Sanofi is a global leader in immunological and inflammatory diseases, and we believe this transaction is a recognition that VTX3232 could potentially offer a disease-modifying approach for the treatment of a number of neuroinflammatory conditions with high unmet medical need. We look forward to strengthening our relationship with Sanofi as the VTX3232 clinical programs progress, with data from the PhaseIIa trial in patients with early Parkinson’s disease and data from the Phase II trial in subjects with obesity and additional cardiometabolic risk factors, both expected in 2025.”

Option on VTX3232

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK